Moleculin Biotech CEO ‘highly encouraged’ by potential of Annamycin

Moleculin Biotech announced the publication of data evaluating Annamycin’s performance as an anthracycline designed to avoid the cardiotoxicity typically associated with currently prescribed anthracyclines. The manuscript titled, "Anthracycline-induced cardiotoxicity – are we about to clear this hurdle?," was published in the peer-reviewed European Journal of Cancer. The published manuscript discusses clinically evaluated doxorubicin analogs that were developed as potentially non-cardiotoxic anticancer agents and includes Annamycin. The anthracycline family of drugs has significantly contributed to marked improvements of overall survival during the last few decades and represents one of the most potent cytostatic drugs for cancer treatment across various histologies. "Despite the major impact of anthracyclines on overall survival in the treatment of a wide spectrum of solid tumors and hematologic malignancies, the development of life-threatening cardiotoxicity still remains a huge challenge for physicians treating cancer patients. Annamycin has consistently demonstrated little to no cardiotoxicity to date and we continue to be highly encouraged by its potential. The discussion throughout this manuscript further demonstrates that the development of non-cardiotoxic anthracyclines is not only feasible, but an elegant and much-needed approach to eliminate this potentially life-threatening adverse event in patients with cancer," commented Walter Klemp, Chairman and CEO of Moleculin. "We look forward to continuing to advance the development of Annamycin with the goal of offering a non-cardiotoxic treatment option for patients."